<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00007033</url>
  </required_header>
  <id_info>
    <org_study_id>199/15488</org_study_id>
    <secondary_id>CHMC-C-91-3-7</secondary_id>
    <nct_id>NCT00007033</nct_id>
  </id_info>
  <brief_title>Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Center for Research Resources (NCRR)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES:

      I. Determine the role of magnesium deficiency in the pathogenesis of decreased serum vitamin
      D and reduced bone density in children with chronic cholestatic liver disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE:

      Patients receive magnesium sulfate IV over 1 hour on day 3. Patients then receive oral
      magnesium gluconate supplementation daily. Treatment with magnesium sulfate repeats once at
      3-6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2000</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>25</enrollment>
  <condition>Alagille Syndrome</condition>
  <condition>Cholestasis</condition>
  <condition>Biliary Atresia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>magnesium gluconate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>magnesium sulfate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

          -  Diagnosis of liver disease with chronic cholestasis Nonsyndromic intrahepatic
             cholestasis Alagille's syndrome Extrahepatic biliary atresia

          -  Direct bilirubin greater than 2 mg/dL OR Bile acids greater than 20 micromoles/L

          -  No hepatic decompensation defined as one or more of the following: Ascites Peripheral
             edema PT at least 4 seconds longer than control Albumin less than 3 g/dL

        --Patient Characteristics--

          -  Renal: No significant renal disease

          -  Cardiovascular: No significant cardiovascular disease

          -  Pulmonary: No significant pulmonary disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Heubi</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Medical Center - Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Heubi JE, Wiechmann DA, Creutzinger V, Setchell KD, Squires R Jr, Couser R, Rhodes P. Tauroursodeoxycholic acid (TUDCA) in the prevention of total parenteral nutrition-associated liver disease. J Pediatr. 2002 Aug;141(2):237-42.</citation>
    <PMID>12183720</PMID>
  </results_reference>
  <verification_date>April 2002</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2000</study_first_submitted>
  <study_first_submitted_qc>December 6, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2000</study_first_posted>
  <last_update_submitted>January 21, 2009</last_update_submitted>
  <last_update_submitted_qc>January 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2009</last_update_posted>
  <keyword>Alagille syndrome</keyword>
  <keyword>biliary atresia</keyword>
  <keyword>cholestasis</keyword>
  <keyword>gastrointestinal disorders</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestasis</mesh_term>
    <mesh_term>Biliary Atresia</mesh_term>
    <mesh_term>Alagille Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

